Literature DB >> 26116087

Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure.

Mouhab Ayas1, Mary Eapen2, Jennifer Le-Rademacher3, Jeanette Carreras2, Hisham Abdel-Azim4, Blanche P Alter5, Paolo Anderlini6, Minoo Battiwalla7, Marc Bierings8, David K Buchbinder9, Carmem Bonfim10, Bruce M Camitta11, Anders L Fasth12, Robert Peter Gale13, Michelle A Lee14, Troy C Lund15, Kasiani C Myers16, Richard F Olsson17, Kristin M Page18, Tim D Prestidge19, Mohamed Radhi20, Ami J Shah21, Kirk R Schultz22, Baldeep Wirk23, John E Wagner15, H Joachim Deeg24.   

Abstract

A second allogeneic hematopoietic cell transplantation (HCT) is the sole salvage option for individuals who develop graft failure after their first HCT. Data on outcomes after second HCT in patients with Fanconi anemia (FA) are scarce. Here we report outcomes after second allogeneic HCT for FA (n = 81). The indication for second HCT was graft failure after the first HCT. Transplantations were performed between 1990 and 2012. The timing of the second HCT predicted subsequent graft failure and survival. Graft failure was high when the second HCT was performed less than 3 months from the first. The 3-month probability of graft failure was 69% when the interval between the first HCT and second HCT was less than 3 months, compared with 23% when the interval was longer (P < .001). Consequently, the 1-year survival rate was substantially lower when the interval between the first and second HCTs was less than 3 months compared with longer (23% vs 58%; P = .001). The corresponding 5-year probability of survival was 16% and 45%, respectively (P = .006). Taken together, these data suggest that fewer than one-half of patients with FA undergoing a second HCT for graft failure are long-term survivors. There is an urgent need to develop strategies to reduce the rate of graft failure after first HCT.
Copyright © 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fanconi anemia; Graft failure; Second transplantation

Mesh:

Year:  2015        PMID: 26116087      PMCID: PMC4568139          DOI: 10.1016/j.bbmt.2015.06.012

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  29 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade.

Authors:  P A Rowlings; D Przepiorka; J P Klein; R P Gale; J R Passweg; P J Henslee-Downey; J Y Cahn; S Calderwood; A Gratwohl; G Socié; M M Abecasis; K A Sobocinski; M J Zhang; M M Horowitz
Journal:  Br J Haematol       Date:  1997-06       Impact factor: 6.998

3.  Bone marrow transplantation from matched siblings in patients with fanconi anemia utilizing low-dose cyclophosphamide, thoracoabdominal radiation and antithymocyte globulin.

Authors:  M Ayas; H Solh; M M Mustafa; M Al-Mahr; I Al-Fawaz; A Al-Jefri; L Shalaby; A Al-Nasser; R Al-Sedairy
Journal:  Bone Marrow Transplant       Date:  2001-01       Impact factor: 5.483

4.  Fludarabine-based conditioning for allogeneic stem cell transplantation for multiply transfused patients with Fanconi's anemia.

Authors:  B George; V Mathews; R V Shaji; V Srivastava; A Srivastava; M Chandy
Journal:  Bone Marrow Transplant       Date:  2005-02       Impact factor: 5.483

5.  Transplantation for Fanconi's anaemia: long-term follow-up of fifty patients transplanted from a sibling donor after low-dose cyclophosphamide and thoraco-abdominal irradiation for conditioning.

Authors:  G Socié; A Devergie; T Girinski; G Piel; P Ribaud; H Esperou; N Parquet; O Maarek; M H Noguera; P Richard; O Brison; E Gluckman
Journal:  Br J Haematol       Date:  1998-10       Impact factor: 6.998

6.  Factors affecting the outcome of related allogeneic hematopoietic cell transplantation in patients with Fanconi Anemia.

Authors:  Mouhab Ayas; Khawar Siddiqui; Abdullah Al-Jefri; Hassan El-Solh; Ali Al-Ahmari; Ashraf Khairy; Samer Markiz; Hasan Shahin; Abdulrahman Al-Musa; Amal Al-Seraihy
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-21       Impact factor: 5.742

7.  Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience.

Authors:  Régis Peffault de Latour; Raphael Porcher; Jean-Hugues Dalle; Mahmoud Aljurf; Elisabeth T Korthof; Johanna Svahn; Roelof Willemze; Cristina Barrenetxea; Valerie Mialou; Jean Soulier; Mouhab Ayas; Rosi Oneto; Andrea Bacigalupo; Judith C W Marsh; Christina Peters; Gerard Socie; Carlo Dufour
Journal:  Blood       Date:  2013-10-21       Impact factor: 22.113

8.  A 20-year perspective on the International Fanconi Anemia Registry (IFAR).

Authors:  David I Kutler; Bhuvanesh Singh; Jaya Satagopan; Sat Dev Batish; Marianne Berwick; Philip F Giampietro; Helmut Hanenberg; Arleen D Auerbach
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

9.  Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study.

Authors:  A Butturini; R P Gale; P C Verlander; B Adler-Brecher; A P Gillio; A D Auerbach
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

10.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

View more
  2 in total

1.  Non-myeloablative conditioning for second hematopoietic cell transplantation for graft failure in patients with non-malignant disorders: a prospective study and review of the literature.

Authors:  K Mallhi; P J Orchard; W P Miller; Q Cao; J Tolar; T C Lund
Journal:  Bone Marrow Transplant       Date:  2017-01-16       Impact factor: 5.483

2.  Graft rejection markers in children undergoing hematopoietic cell transplant for bone marrow failure.

Authors:  Anthony Sabulski; Kasiani C Myers; Jack J Bleesing; Alexandra Duell; Adam Lane; Ashley Teusink-Cross; Stella M Davies; Sonata Jodele
Journal:  Blood Adv       Date:  2021-11-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.